Gonadorelin
Gonadorelin is synthetic gonadotropin-releasing hormone, a ten-amino-acid hypothalamic hormone also called GnRH or LHRH.
The short version
- Why people discuss it
- Discussed for fertility and testicular-function preservation during TRT; intermittent community injections do not establish the effects of specialist pulsatile treatment. Community interest does not establish benefit or a suitable treatment.
- What it is
- Gonadorelin is synthetic gonadotropin-releasing hormone, a ten-amino-acid hypothalamic hormone also called GnRH or LHRH.
- Biggest caution
- Pulsatile administration, diagnostic use and other routes answer different clinical questions. Those settings do not establish a community fertility or hormone-restoration protocol.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 50–150 mcg
- Frequency
- 2–3 times weekly
- Duration / phase
- 4–8 weeks
One publisher’s reported example. Older sources instead describe 100–200 mcg once or twice daily. Neither schedule is equivalent to specialist pulsatile GnRH pump treatment; preservation of fertility during TRT is not established by these reports. Reference only; this does not establish safety, effectiveness or individual suitability.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
50–150 mcg SC 2–3 times/week, 4–8 weeks; distinct 14-day daily post-cycle example.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27